113 related articles for article (PubMed ID: 24330085)
21. Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor.
Carlsson K; Freskgård PO; Persson E; Carlsson U; Svensson M
Eur J Biochem; 2003 Jun; 270(12):2576-82. PubMed ID: 12787023
[TBL] [Abstract][Full Text] [Related]
22. Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Pacheco MT; Berra CM; Morais KL; Sciani JM; Branco VG; Bosch RV; Chudzinski-Tavassi AM
PLoS One; 2014; 9(12):e111907. PubMed ID: 25479096
[TBL] [Abstract][Full Text] [Related]
23. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors.
Kopp CW; Siegel JB; Hancock WW; Anrather J; Winkler H; Geczy CL; Kaczmarek E; Bach FH; Robson SC
Transplantation; 1997 Mar; 63(5):749-58. PubMed ID: 9075849
[TBL] [Abstract][Full Text] [Related]
24. Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Pacheco MT; Morais KL; Berra CM; Demasi M; Sciani JM; Branco VG; Bosch RV; Iqbal A; Chudzinski-Tavassi AM
Exp Cell Res; 2016 Jan; 340(2):248-58. PubMed ID: 26748183
[TBL] [Abstract][Full Text] [Related]
25. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.
Han X; Girard TJ; Baum P; Abendschein DR; Broze GJ
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2563-7. PubMed ID: 10521388
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory properties of human recombinant Arg24-->Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2).
Kamei S; Petersen LC; Sprecher CA; Foster DC; Kisiel W
Thromb Res; 1999 May; 94(3):147-52. PubMed ID: 10326761
[TBL] [Abstract][Full Text] [Related]
27. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
28. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
29. Recombinant expression of Ixolaris, a Kunitz-type inhibitor from the tick salivary gland, for NMR studies.
De Paula VS; Silva FHS; Francischetti IMB; Monteiro RQ; Valente AP
Protein Expr Purif; 2017 Nov; 139():49-56. PubMed ID: 28734839
[TBL] [Abstract][Full Text] [Related]
30. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
31. NMR solution structure of the recombinant tick anticoagulant protein (rTAP), a factor Xa inhibitor from the tick Ornithodoros moubata.
Antuch W; Güntert P; Billeter M; Hawthorne T; Grossenbacher H; Wüthrich K
FEBS Lett; 1994 Sep; 352(2):251-7. PubMed ID: 7925983
[TBL] [Abstract][Full Text] [Related]
32. Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis.
Drewes CC; Dias RY; Hebeda CB; Simons SM; Barreto SA; Ferreira JM; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2012 Sep; 60(3):333-40. PubMed ID: 22575283
[TBL] [Abstract][Full Text] [Related]
33. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
Enjyoji K; Miyata T; Kamikubo Y; Kato H
Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433
[TBL] [Abstract][Full Text] [Related]
34. The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor.
Ettelaie C; Adam JM; James NJ; Oke AO; Harrison JA; Bunce TD; Bruckdorfer KR
FEBS Lett; 1999 Dec; 463(3):341-4. PubMed ID: 10606750
[TBL] [Abstract][Full Text] [Related]
35. [Tissue factor pathway inhibitor (TFPI) and its role in pathology].
Rucińska M; Gacko M; Skrzydlewski Z
Postepy Hig Med Dosw; 1997; 51(4):421-30. PubMed ID: 9446103
[TBL] [Abstract][Full Text] [Related]
36. Tissue factor pathway inhibitor: structure, biology and involvement in disease.
Lwaleed BA; Bass PS
J Pathol; 2006 Feb; 208(3):327-39. PubMed ID: 16261634
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
38. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
[TBL] [Abstract][Full Text] [Related]
39. Purification of tissue factor pathway inhibitor (TFPI) from rabbit plasma and characterization of its differences from TFPI isolated from human plasma.
Warn-Cramer BJ; Maki SL
Thromb Res; 1992 Aug; 67(4):367-83. PubMed ID: 1412217
[TBL] [Abstract][Full Text] [Related]
40. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI.
Kamei S; Kamikubo Y; Hamuro T; Fujimoto H; Ishihara M; Yonemura H; Miyamoto S; Funatsu A; Enjyoji K; Abumiya T
J Biochem; 1994 Apr; 115(4):708-14. PubMed ID: 8089087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
